← Leaderboards
Paul Guyre
Dartmouth College
$11,099,477
Attributed
$11,099,477
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2005–21$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$11,099,477 · 11
By mechanism
R44$6,266,981 · 3
R01$2,459,949 · 2
R43$896,895 · 3
P30$883,152 · 1
R21$434,500 · 1
R03$158,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Dartmouth College
Same institution · by research overlap
- Michael W Fanger$14,545,255
- Ebo Derk De Muinck$1,758,012
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoDoseProductionToxic EffectMacrophageSafetyCytokineBaseFlow CytometryClinical ResearchIn VitroLipopolysaccharidesGlucocorticoidsInfectionCessation Of LifeTissue /Cell CultureTechnologyPreventMonocyteHalf-LifeCd AntigensMeetingsEngineeringEfficacy Study
Grant awards (27)
Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus$984,986
R44 · FY2021 · AI · contact PI
Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus$962,825
R44 · FY2020 · AI · contact PI
Biomarker of IAPP dysfunction in prediabetes and early type 2 diabetes mellitus (T2DM)$299,152
R43 · FY2020 · DK · contact PI
Antimicrobial peptides to combat MDR ESKAPE pathogens$298,691
R43 · FY2019 · AI · contact PI
Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus$295,147
R44 · FY2019 · AI · contact PI
Development of GIFT4: a B cell focused immunotherapy for cancer$999,997
R44 · FY2018 · CA · contact PI
Preclinical development of inhalable glutaredoxin-1 for the treatment of IPF$749,685
R44 · FY2018 · HL · contact PI
Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus$299,913
R44 · FY2018 · AI · contact PI
Development of GIFT4: a B cell focused immunotherapy for cancer$999,088
R44 · FY2017 · CA · contact PI
Preclinical development of inhalable glutaredoxin-1 for the treatment of IPF$750,396
R44 · FY2017 · HL · contact PI
Preclinical Development of BILT, a Next-Generation Immunotoxin Therapy for CTCL$299,052
R43 · FY2015 · CA · contact PI
Preclinical development of inhalable glutaredoxin-1 for the treatment of IPF$224,944
R44 · FY2015 · HL · contact PI
Physiological vs. pharmacological effects of glucocorticoids on human monocytes.$158,000
R21 · FY2012 · AI · contact PI
Physiological vs. pharmacological effects of glucocorticoids on human monocytes.$276,500
R21 · FY2011 · AI · contact PI
Glucocorticoid/cytokine mechanisms in endotoxemia.$374,531
R01 · FY2007 · AI · contact PI
Glucocorticoid/cytokine mechanisms in endotoxemia.$385,718
R01 · FY2006 · AI · contact PI
Glucocorticoid/cytokine mechanisms in endotoxemia.$395,000
R01 · FY2005 · AI
Glucocorticoid/cytokine mechanisms in endotoxemia.$395,000
R01 · FY2004 · AI
Glucocorticoid/cytokine mechanisms in endotoxemia.$395,000
R01 · FY2003 · AI
Regulation and Function of Macrophage CD163$79,000
R03 · FY2003 · AI
CORE--FLOW CYTOMETRY AND FLUORESCENCE IMAGING FACILITY$248,412
P30 · FY2002 · CA
Regulation and Function of Macrophage CD163$79,000
R03 · FY2002 · AI
REDIRECTING THE IMMUNE RESPONSE TO ALLERGENS$261,154
R01 · FY2001 · AI
CORE--FLOW CYTOMETRY AND FLUORESCENCE IMAGING FACILITY$248,412
P30 · FY2001 · CA
REDIRECTING THE IMMUNE RESPONSE TO ALLERGENS$253,546
R01 · FY2000 · AI
CORE--FLOW CYTOMETRY AND FLUORESCENCE IMAGING FACILITY$248,412
P30 · FY2000 · CA
CORE--FLOW CYTOMETRY AND FLUORESCENCE IMAGING FACILITY$137,916
P30 · FY2000 · CA